139481-33-7

Basic information

• Product Name: Azilsartan iMpurity I
• Synonyms: Azilsartan iMpurity I;Methyl 1-((2'-cyanobiphenyl-4-yl) Methyl)-2H-benziMidazol-2-one-7-carboxylate);Methyl 3-((2'-cyanobiphenyl-4-yl)Methyl)-2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-4-carboxylate;methyl 3-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate;zilsartan iMpurity I
• CAS NO: 139481-33-7
• Molecular Formula: C₂₃H₁₇N₃O₃
• Molecular Weight: 383.39938
• Mol File: 139481-33-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: 11.32±0.30(Predicted)
• CAS DataBase Reference: Azilsartan iMpurity I(CAS DataBase Reference)
• NIST Chemistry Reference: Azilsartan iMpurity I(139481-33-7)
• EPA Substance Registry System: Azilsartan iMpurity I(139481-33-7)

Safety Data

• Hazardous Substances Data: 139481-33-7(Hazardous Substances Data)

Usage

Description

Azilsartan iMpurity I, also known as Methyl 3-[(2''-Cyano[1,1''-biphenyl]-4-yl)methyl]-2,3-dihydro-2-oxo-1H-benzimidazole-4-carboxylate, is an impurity found in Azilsartan (A926900). Azilsartan is an analgesic and anti-inflammatory drug that contains angiotensin II antagonists, which are used to treat hypertension and other related conditions.

Uses

Used in Pharmaceutical Industry:
Azilsartan iMpurity I is used as an impurity in the manufacturing process of Azilsartan, an analgesic and anti-inflammatory drug. Its presence is crucial for ensuring the quality and safety of the final drug product, as it helps in monitoring and controlling the purity of the active pharmaceutical ingredient (API).
Azilsartan iMpurity I is used as a reference material for the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC) and other chromatographic techniques. This helps in the accurate quantification and identification of the impurity in the drug product, ensuring compliance with regulatory guidelines and maintaining the overall quality of the medication.
Additionally, Azilsartan iMpurity I can be used in research and development for the study of the pharmacological effects and potential interactions of the impurity with the main API, Azilsartan. This information can be valuable in understanding the overall safety profile and efficacy of the drug, as well as in the development of new drug formulations or alternative treatments for hypertension and related conditions.

Upstream product

• 139481-35-9 methyl 2-<<(2'-cyanobiphenyl-4-yl)methyl>amino>-3-<(methoxycarbonyl)amino>benzoate 
• 139481-44-0 methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-benzimidazole-7-carboxylate 
• 139481-41-7 ethyl 1-[(2'-cyano-[1,1']-biphenyl-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate 
• 139481-38-2 methyl 2-amino>-3-nitrobenzoate 
• 139481-28-0 methyl 2-<<2'-cyanobiphenyl-4-yl)methyl>amino>-3-nitrobenzoate 
• 136304-78-4 methyl 3-amino-2-[[(2'-cyanobiphenyl-4-yl)methyl]amino]benzoate 
• 856414-36-3 2-Azidocarbonyl-3-nitro-benzoic acid methyl ester 
• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 

Downstream Products

• 139481-34-8 methyl 2-chloro-1-<(2'-cyanobiphenyl-4-yl)methyl>-1H-benzimidazole-7-carboxylate 
• 1499167-72-4 methyl 3-((2'-(N'-hydroxycarbamimidoyl)biphenyl-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate 
• 139481-97-3 2-Morpholin-4-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-98-4 2-Piperidin-1-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-51-9 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-morpholino-1H-benzimidazole-7-carboxylate 
• 139481-52-0 methyl 1-<(2'-cyanobiphenyl-4-yl)methyl>-2-piperidino-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

A [...] process impurity D synthetic method

The invention discloses a process of impurity D [...] synthetic method. To methyl [...] A1 as raw materials, under acidic conditions to produce intermediate de-ethyl A2, intermediate A2 through hydrolysis to produce intermediate A3, A3 and then with hydro

A METHOD OF MANUFACTURING 2-ETHOXY-1-((2'-((HYDROXYAMINO) IMINOMETHYL)BIPHENYL-4- YL)METHYL)-1H-BENZO [D] IMIDAZOLE-7-CARBOXYLIC ACID AND ITS ESTERS

A method of manufacturing 2-ethoxy-1 -((2'-((hydroxyamino)iminomethyl)biphenyl-4- yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid and its esters of formula I, wherein R is either H or an (un)branched C1-C4 alkyl, ArCH2, Ar2CH, or Ar3C, wherein Ar is a (un)substituted phenyl, the key intermediates for the synthesis of azilsartan, the reaction of the corresponding nitrile of formula IV being carried out with aqueous hydroxylamine in a polar aprotic solvent, or in a mixture of such solvents.

COMPOUND WHICH IS ANGIOTENSIN II ANTAGONIST

-